Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease By Ogkologos - September 22, 2025 217 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients... October 18, 2021 Sodium Thiosulfate Prevents Cisplatin-Induced Hearing Loss in Some Children July 13, 2018 Firefighters Band Together To Raise $30k For Breast Cancer Research &... September 24, 2021 Discover and translate – a mantra to work by October 17, 2022 Load more HOT NEWS FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC Addressing Mental Health Needs of Adolescent and Young Adult Cancer Survivors CAR22 Shows Durable Efficacy After a Single Infusion in Patients with... Fewer Women with Ovarian, Breast Cancer Undergo Genetic Testing than Expected
